Journal of Clinical Pharmacy and Therapeutics

Volume 47, Issue 5 pp. 609-618

ORIGINAL ARTICLE

Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer

Mengjia Shen MD, PhD,

Mengjia Shen MD, PhD

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Libo Yang MD, PhD,

Libo Yang MD, PhD

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Ting Lei MD, PhD,

Ting Lei MD, PhD

Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China

Search for more papers by this author

Peichuan Zhang MS,

Peichuan Zhang MS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Lin Xiao BS,

Lin Xiao BS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Shiyu Cao MS,

Shiyu Cao MS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Fei Chen BS,

Fei Chen BS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Li Li MS,

Li Li MS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Feng Ye PhD,

Feng Ye PhD

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Hong Bu MD, PhD,

Corresponding Author

Hong Bu MD, PhD

[email protected]

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Correspondence

Hong Bu, Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China, Department of Pathology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, Sichuan, China, Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

Email: [email protected]

Search for more papers by this author

Mengjia Shen MD, PhD,

Mengjia Shen MD, PhD

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Libo Yang MD, PhD,

Libo Yang MD, PhD

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Ting Lei MD, PhD,

Ting Lei MD, PhD

Department of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China

Search for more papers by this author

Peichuan Zhang MS,

Peichuan Zhang MS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Lin Xiao BS,

Lin Xiao BS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Shiyu Cao MS,

Shiyu Cao MS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Fei Chen BS,

Fei Chen BS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Li Li MS,

Li Li MS

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Feng Ye PhD,

Feng Ye PhD

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Search for more papers by this author

Hong Bu MD, PhD,

Corresponding Author

Hong Bu MD, PhD

[email protected]

Institute of Clinical Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Key Lab of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Correspondence

Email: [email protected]

Search for more papers by this author

First published: 28 February 2022

https://doi.org/10.1111/jcpt.13580

Citations: 3

Funding information

The authors did not receive support from any organization for the submitted work.

Share a link

Email
Wechat
Bluesky

Abstract

What is known and Objective

Compared with other molecular subtypes, hormone receptor-positive breast cancer often shows worse neoadjuvant chemotherapy efficacy. This study aims to explore the relationship between the oestrogen receptor (ER)-related genes carbonic anhydrase 12 (CA12) and trefoil factor 3 (TFF3) and their predictive value of neoadjuvant chemotherapy for breast cancer.

Methods

We investigated the relationships between CA12, TFF3 and ER status and their predictive value of anthracycline-taxane neoadjuvant chemotherapy in 115 female breast cancer patients via real-time polymerase chain reaction (RT-PCR) and 4 GEO datasets: GSE41998, GSE25065, GSE20194 and GSE20271. Then, the effects of CA12 and TFF3 on the chemotherapy drugs doxorubicin and docetaxel were verified in vitro in the breast cancer cell lines MCF-7 and BT474.

Results and Discussion

The GEO datasets and RT-PCR results showed that the relative expression of both CA12 and TFF3 was higher in oestrogen receptor-positive samples compared with the other samples (p < 0.05). CA12 was significantly correlated with TFF3 (p < 0.05). In MCF-7 cells, inhibition of TFF3 induced downregulation of CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 also downregulated TFF3 and ESR1 (p < 0.05). In BT474 cells, inhibition of TFF3 downregulated CA12 and ESR1 (p < 0.05) at both the mRNA and the protein levels, while inhibition of CA12 led to slight upregulation of TFF3 and ESR1 (p > 0.05). Moreover, GEO datasets and RT-PCR results showed that CA12 and TFF3 were more highly expressed in nonpathological complete response (non-pCR) samples than in pCR samples (p < 0.05). Cell viability assays of MCF-7 and BT474 cells showed that inhibiting CA12 and TFF3 could enhance sensitivity to doxorubicin and docetaxel (p < 0.05).

What is new and Conclusion

CA12 and TFF3 were correlated with each other, and their high expression might explain the worse efficacy of neoadjuvant chemotherapy in oestrogen receptor-positive breast cancer patients.

CONFLICTS OF INTEREST

No conflicts of interest have been declared.

Open Research

DATA AVAILABILITY STATEMENT

The datasets analysed during the current study are available in the GEO database (https://www.ncbi.nlm.nih.gov/geo/).

REFERENCE

1DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6): 438–451.
10.3322/caac.21583
PubMed Web of Science® Google Scholar
2Capelôa T, Benyahia Z, Zampieri LX, et al. Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines. Semin Cell Dev Biol. 2020; 98: 181-191.
10.1016/j.semcdb.2019.05.006
CAS PubMed Web of Science® Google Scholar
3Pucci P, Rescigno P, Sumanasuriya S, et al. Hypoxia and Noncoding RNAs in Taxane Resistance. Trends Pharmacol Sci. 2018; 39(8): 695-709.
10.1016/j.tips.2018.05.002
CAS PubMed Web of Science® Google Scholar
4Haque W, Verma V, Hatch S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018; 170(3): 559-567.
10.1007/s10549-018-4801-3
CAS PubMed Web of Science® Google Scholar
5Tozlu S, Girault I, Vacher S, et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer. 2006; 13(4): 1109-1120.
10.1677/erc.1.01120
CAS PubMed Web of Science® Google Scholar
6Wykoff CC, Beasley N, Watson PH, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol. 2001; 158(3): 1011-1019.
10.1016/S0002-9440(10)64048-5
CAS PubMed Web of Science® Google Scholar
7Furuta GT, Turner JR, Taylor CT, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001; 193(9): 1027-1034.
10.1084/jem.193.9.1027
CAS PubMed Web of Science® Google Scholar
8Kopecka J, Campia I, Jacobs A, et al. Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells. Oncotarget. 2015; 6(9): 6776-6793.
10.18632/oncotarget.2882
PubMed Google Scholar
9Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem. 1995; 64: 375-401.
10.1146/annurev.bi.64.070195.002111
CAS PubMed Web of Science® Google Scholar
10Parkkila S, Parkkila AK, Saarnio J, et al. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J Histochem Cytochem. 2000; 48(12): 1601-1608.
10.1177/002215540004801203
CAS PubMed Web of Science® Google Scholar
11Ilie MI, Hofman V, Ortholan C, et al. Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer. 2011; 128(7): 1614-1623.
10.1002/ijc.25491
CAS PubMed Web of Science® Google Scholar
12Kivelä A, Parkkila S, Saarnio J, et al. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol. 2000; 156(2): 577-584.
10.1016/S0002-9440(10)64762-1
CAS PubMed Web of Science® Google Scholar
13Nordfors K, Haapasalo J, Korja M, et al. The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer. 2010; 10: 148.
10.1186/1471-2407-10-148
CAS PubMed Web of Science® Google Scholar
14Hynninen P, Vaskivuo L, Saarnio J, et al. Expression of transmembrane carbonic anhydrases IX and XII in ovarian tumours. Histopathology. 2006; 49(6): 594-602.
10.1111/j.1365-2559.2006.02523.x
CAS PubMed Web of Science® Google Scholar
15Watson PH, Chia SK, Wykoff CC, et al. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer. 2003; 88(7): 1065-1070.
10.1038/sj.bjc.6600796
CAS PubMed Web of Science® Google Scholar
16Chien M-H, Ying T-H, Hsieh Y-H, et al. Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol. 2012; 48(5): 417-423.
10.1016/j.oraloncology.2011.11.015
CAS PubMed Web of Science® Google Scholar
17Williams GR, Wright NA. Trefoil factor family domain peptides. Virchows Arch. 1997; 431(5): 299-304.
10.1007/s004280050102
CAS PubMed Web of Science® Google Scholar
18Aihara E, Engevik KA, Montrose MH. Trefoil Factor Peptides and Gastrointestinal Function. Annu Rev Physiol. 2017; 79: 357-380.
10.1146/annurev-physiol-021115-105447
CAS PubMed Web of Science® Google Scholar
19Osako T, Nishimura R, Okumura Y, et al. Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. Exp Ther Med. 2012; 3(1): 66-71.
10.3892/etm.2011.359
CAS PubMed Web of Science® Google Scholar
20Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008; 14(24): 8019-8026.
10.1158/1078-0432.CCR-08-0974
CAS PubMed Web of Science® Google Scholar
21Vergara D, Ravaioli S, Fonzi E, et al. Carbonic Anhydrase XII Expression Is Modulated during Epithelial Mesenchymal Transition and Regulated through Protein Kinase C Signaling. Int J Mol Sci. 2020; 21(3).
10.3390/ijms21030715
Web of Science® Google Scholar
22Yen T-Y, Macher BA, McDonald CA, et al. Glycoprotein profiles of human breast cells demonstrate a clear clustering of normal/benign versus malignant cell lines and basal versus luminal cell lines. J Proteome Res. 2012; 11(2): 656-667.
10.1021/pr201041j
CAS PubMed Web of Science® Google Scholar
23Barnett DH, Sheng S, Howe Charn T, et al. Estrogen receptor regulation of carbonic anhydrase XII through a distal enhancer in breast cancer. Can Res. 2008; 68(9): 3505-3515.
10.1158/0008-5472.CAN-07-6151
CAS PubMed Web of Science® Google Scholar
24Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006; 25(28): 3994-4008.
10.1038/sj.onc.1209415
CAS PubMed Web of Science® Google Scholar
25Ahmed ARH, Griffiths AB, Tilby MT, et al. TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol. 2012; 180(3): 904-916.
10.1016/j.ajpath.2011.11.022
CAS PubMed Web of Science® Google Scholar
26Laganière J, Deblois G, Lefebvre C, et al. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci USA. 2005; 102(33): 11651-11656.
10.1073/pnas.0505575102
CAS PubMed Web of Science® Google Scholar
27Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Can Res. 2000; 60(24): 7075-7083.
CAS PubMed Web of Science® Google Scholar
28Chiche J, Ilc K, Laferrière J, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Can Res. 2009; 69(1): 358-368.
10.1158/0008-5472.CAN-08-2470
CAS PubMed Web of Science® Google Scholar
29Diao S, Zheng Q, Gao J, et al. Trefoil factor 3 contributes to the malignancy of glioma via regulating HIF-1α. Oncotarget. 2017; 8(44): 76770-76782.
10.18632/oncotarget.20010
PubMed Google Scholar
30Kopecka J, Rankin GM, Salaroglio IC, et al. P-glycoprotein-mediated chemoresistance is reversed by carbonic anhydrase XII inhibitors. Oncotarget. 2016; 7(52): 85861-85875.
10.18632/oncotarget.13040
PubMed Google Scholar
31Miller WR, Larionov A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Research : BCR. 2010; 12(4): R52.
10.1186/bcr2611
PubMed Web of Science® Google Scholar
32Kannan N, Kang J, Kong X, et al. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010; 12(12): 1041-1053.
10.1593/neo.10916
CAS PubMed Web of Science® Google Scholar
33Taylor KJ, Sims AH, Liang L, et al. Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Research : BCR. 2010; 12(3): R39.
10.1186/bcr2593
PubMed Web of Science® Google Scholar
34Chen Y, Chen C, Yang B, et al. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett. 2011; 302(1): 63-68.
10.1016/j.canlet.2010.12.014
CAS PubMed Web of Science® Google Scholar
35You M-L, Chen Y-J, Chong Q-Y, et al. Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent. Oncotarget. 2017; 8(24): 39323-39344.
10.18632/oncotarget.16950
PubMed Web of Science® Google Scholar
36Wu H, Gu J, Zhou D, et al. LINC00160 mediated paclitaxel-And doxorubicin-resistance in breast cancer cells by regulating TFF3 via transcription factor C/EBPβ. J Cell Mol Med. 2020.
10.1111/jcmm.15487
Web of Science® Google Scholar
37Poh HM, Chiou YS, Chong QY, et al. Inhibition of TFF3 Enhances Sensitivity-and Overcomes Acquired Resistance-to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma. Cancers (Basel). 2019; 11(10).
10.3390/cancers11101528
Web of Science® Google Scholar
38Yuan Z, Chen D, Chen X, et al. Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells. Cancer Cell Int. 2017; 17: 7.
10.1186/s12935-016-0379-1
PubMed Web of Science® Google Scholar
39Al-Salam S, Sudhadevi M, Awwad A, et al. Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy. BMC Cancer. 2019; 19(1): 135.
10.1186/s12885-019-5316-y
PubMed Web of Science® Google Scholar

Citing Literature

All articles

Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer

Abstract

What is known and Objective

Methods

Results and Discussion

What is new and Conclusion

CONFLICTS OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCE

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Correlation between CA12 and TFF3 and their prediction value of neoadjuvant chemotherapy response in breast cancer

Abstract

What is known and Objective

Methods

Results and Discussion

What is new and Conclusion

CONFLICTS OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCE

Citing Literature

References

Related

Information